Berlin, 21.09.2021 (GA2LEN UCARE Network). Burning, itching, pain - more than one percent of the world’s population suffers from chronic urticaria (hives) and the number is growing. Unfortunately, this disease still receives too little public attention. The GA²LEN UCARE Network, the Urticaria Network (UNEV) and the German Allergy and Asthma Association (DAAB) have therefore been initiating World...
In this episode, our host is joined by Dr Ivan Chérrez Ojeda, an urticariologist and communication technology enthusiast, to discuss the potential application of telemedicine in the management of patients with chronic urticaria.
Could targeting cytokines produced by autoreactive T cells benefit patients with chronic spontaneous urticaria (CSU)? Professor Marcus Maurer is joined by Professor Elias Toubi to discuss the role of T cells in CSU.
At EAACI 2021 touchIMMUNOLOGY has joined Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the rationale behind avapritinib for advanced systemic mastocytosis and the results of the PATHFINDER study.
At EAACI 2021 touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria.
In this episode, Dr Young-Min Ye shares the findings of her cutting-edge research into predictors of remission in chronic urticaria, and explains what is currently known about the role of Mas-related G protein coupled receptor X2 (MRGPRX2) in the activation of mast cells.
How do comorbidities affect patients with chronic spontaneous urticaria and what can be done to minimise their impact? Find out more on this crucial, yet understudied topic from our latest guest, Dr Simon Francis Thomsen.
In this episode, our host is joined by Dr Moshe Ben-Shoshan, who shares his pioneering approach to treating paediatric patients and draws on his experience to debunk some of the common myths surrounding childhood urticaria.